Esperion Therapeutics has patented a method for acquiring, preserving, and administering delipidated plasma containing pre-beta HDL. The process involves testing, preserving, and retesting the plasma to ensure the pre-beta HDL remains effective for up to three years before administration to patients. GlobalData’s report on Esperion Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Esperion Therapeutics, NSAID cancer drugs was a key innovation area identified from patents. Esperion Therapeutics's grant share as of February 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.
Preserving and administering pre-beta high density lipoprotein plasma
A recently granted patent (Publication Number: US11903965B2) outlines a method for preserving pre-beta high density lipoprotein for administration to patients. The method involves obtaining delipidated plasma containing the pre-beta high density lipoprotein, testing the concentration of the protein, preserving the plasma for a period ranging from one week to three years, and then preparing it for administration. The preserved plasma is tested again to ensure the concentration of the pre-beta high density lipoprotein is above an acceptable threshold level before being administered to the patient. The process includes steps such as modifying the protein concentration, freezing the batch at temperatures below -30°C, and thawing the plasma in a specific temperature range before administration.
Additionally, the patent describes a method for preserving modified high density lipoproteins for patient administration. This method involves obtaining delipidated plasma containing the modified high density lipoproteins, testing the concentration of the protein, preserving the plasma for a specified period, and preparing it for administration after confirming the protein concentration is within an acceptable range. Similar to the previous method, steps such as modifying the protein concentration, freezing the batch at temperatures below -30°C, and storing the thawed plasma at specific temperatures for a limited time are outlined. The patent aims to provide a detailed process for preserving and administering high density lipoproteins to patients, ensuring the efficacy and safety of the treatment.
To know more about GlobalData’s detailed insights on Esperion Therapeutics, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
